Les scientifiques impliqués affirment que ces résultats pourraient marquer un tournant dans le traitement du cancer, rapprochant ainsi la médecine personnalisée.

The findings, mark one of the clearest signs yet that mRNA technology, the same platform used in some Covid vaccines can be ...

Moderna gave investors a scare as its stock plunged on Thursday. But it's still one of the hottest biotechs this year. And it's hardly alone – the sector is on a roll and looks poised for more gains.

The latest big rally began in August, when Moderna and partner Merck said their personalized shot cut the risk of melanoma returning after surgery in a large trial. The stock nearly quadrupled in two ...

Moderna and Merck's personalized mRNA vaccine reduced melanoma recurrence/death risk by 42% in Phase 3 trials, but Moderna's ...

Moderna cancer vaccine data confirms a 42% cut in melanoma recurrence risk, but an ESMO embargo breach triggered wild swings ...

A personalised cancer vaccine developed by Moderna and Merck shows promise in reducing melanoma metastasis risk by 38% using ...

A world-first personalized cancer vaccine has been shown to cut the risk of melanoma returning or resulting in death by 42% ...

A study of a personalized vaccine combined with an existing immunotherapy found the treatment helped patients with melanoma avoid cancer recurrence. The combination trains the patient's immune system ...

UK retail volumes fell 0.4% in September as warm weather curbed autumn purchases; Q3 still rose 0.7%, but rising energy, fuel ...

National Bank trims policy rate to 15.75% after inflation dropped to 9.3%; further cuts unlikely this year or before end of ...

When the news arrived in August that what could be the first personalized mRNA cancer vaccine had succeeded in a late-stage clinical trial<a class="excerpt-read-more" href=" More ...